Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza, Fernando C; Appel, Gerald B; Barbour, Sean J; Rovin, Brad H; Lafayette, Richard A; Aslam, Nabeel; Jefferson, Jonathan A; Gipson, Patrick E; Rizk, Dana V; Sedor, John R; Simon, James F; McCarthy, Ellen T; Brenchley, Paul; Sethi, Sanjeev; Avila-Casado, Carmen; Beanlands, Heather; Lieske, John C; Philibert, David; Li, Tingting; Thomas, Lesley F; Green, Dolly F; Juncos, Luis A; Beara-Lasic, Lada; Blumenthal, Samuel S; Sussman, Amy N; Erickson, Stephen B; Hladunewich, Michelle; Canetta, Pietro A; Hebert, Lee A; Leung, Nelson; Radhakrishnan, Jay; Reich, Heather N; Parikh, Samir V; Gipson, Debbie S; Lee, Dominic K; da Costa, Bruno R; Jüni, Peter; Cattran, Daniel C.
N Engl J Med
; 381(1): 36-46, 2019 07 04.
Artigo em Inglês | MEDLINE | ID: mdl-31269364
A First Step toward a New Approach to Treating Membranous Nephropathy.
Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients.
Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.
Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis.
Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study.
A clinical audit of high-cost and off-label drug use in dermatology.
Cyclosporin A for primary biliary cirrhosis.
Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.
Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.